Search This Blog

Tuesday, June 30, 2015

Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma (NYSE:LLY)

INDIANAPOLIS and OXFORD, EnglandJune 29, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Immunocore Limited today announced that they have entered into an immunotherapy-based clinical trial collaboration to explore the utility of Immunocore's lead T cell receptor-based investigational therapeutic, IMCgp100, in combination with Lilly's galunisertib (LY2157299) and merestinib (LY2801653) for the treatment of melanoma. The goal of the collaboration is to identify combination regimens that provide synergies in efficacy and durability in patients with metastatic cutaneous and uveal melanomas.



Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.